RLAY Dividend: Relay Therapeutics Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

RLAY Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	8	10	25	1	3	82
Revenue Growth (YoY)	-77%	-60%	2,400%	-67%	-96%	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	61	76	74	65	57	38
Research & Development	283	319	330	246	292	96
Operating Expenses	335	382	398	300	355	138
Other Non Operating Income (Expenses)	0	0	0	0	0	0
Pretax Income	-297	-337	-341	-290	-363	-52
Income Tax Expense	--	--	--	--	--	--
Net Income	-297	-337	-341	-290	-363	-230
Net Income Growth	-51%	-1%	18%	-20%	57.99%	206.99%
Shares Outstanding (Diluted)	172.38	142.86	122.57	112.23	95.14	89.91
Shares Change (YoY)	23%	17%	9%	18%	6%	3%
EPS (Diluted)	-1.72	-2.36	-2.78	-2.59	-3.82	-2.56
EPS Growth	-60%	-15%	8%	-32%	49%	194%
Free Cash Flow	-248	-251	-304	-238	-77	-104
Free Cash Flow Per Share	-1.43	-1.75	-2.48	-2.12	-0.8	-1.15
Gross Margin	--	--	--	--	--	--
Operating Margin	-4,087.5%	-3,720%	-1,492%	-29,900%	-11,733.33%	-67.07%
Profit Margin	-3,712.5%	-3,370%	-1,364%	-29,000%	-12,100%	-280.48%
Free Cash Flow Margin	-3,100%	-2,510%	-1,216%	-23,800%	-2,566.66%	-126.82%
EBITDA	-323	-367	-368	-295	-349	-53
EBITDA Margin	-4,037.5%	-3,670%	-1,472%	-29,500%	-11,633.33%	-64.63%
D&A For EBITDA	4	5	5	4	3	2
EBIT	-327	-372	-373	-299	-352	-55
EBIT Margin	-4,087.5%	-3,720%	-1,492%	-29,900%	-11,733.33%	-67.07%
Effective Tax Rate	--	--	--	--	--	--